Laurus Labs

Last updated

Laurus Labs Limited
Company type Public
NSE:  LAURUSLABS
BSE:  540222
Industry Pharmaceuticals
Founded2005;19 years ago (2005) [1]
FounderSatyanarayana Chava
Headquarters
Hyderabad, Telangana
,
India [2]
Number of locations
6
Area served
Global
Key people
    • Satyanarayana Chava (CEO)
    • Vantaram Venkata Ravi Kumar (CFO) [3] [4]
Products Formulations
Active pharmaceutical ingredients Speciality Chemicals, Agro Chemicals
ServicesCustom synthesis
Contract development and manufacturing organization
Fermentation
RevenueIncrease2.svg₹6,040 crore (US$760 million) (FY23) [5]
Decrease2.svg₹796 crore (US$100 million) (FY23) [5]
Number of employees
5,700 (2022) [6]
Divisions Laurus Generics
Laurus Synthesis
Laurus Bio
Subsidiaries
  • Laurus Synthesis
  • Laurus Bio
  • Laurus Speciality Chemicals
  • Sriam Labs
Website www.lauruslabs.com

Laurus Labs is an Indian multinational pharmaceutical and biotechnology company headquartered in Hyderabad. Its focus areas include active pharmaceutical ingredients (APIs), generic formulations, custom synthesis (CDMO), biotechnology, [7] veterinary APIs and agrochemicals. The company was founded in 2005 by Satyanarayana Chava. [8]

Contents

Laurus Labs has its eight manufacturing plants located at Visakhapatnam, Hyderabad and Bangalore. The manufacturing units have received one or more approvals from USFDA, WHO, NIP Hungary, KFDA, MHRA, TGA, and PMDA. [9] The company operates through its subsidiaries in Europe and United States and also offers its services in contract research, clinical research and analytical research through its R&D centers.[ citation needed ] The R&D centres are based in Hyderabad, Visakhapatnam and United States.

Business divisions

The company has 4 business divisions, which are generic formulation (FDF), generic APIs, contract development and manufacturing (CDMO)-Synthesis, biotechnology [10] and speciality chemicals.

Generic formulation (FDF)

In March 2020, Laurus Labs received US Food and Drug Administration approval to market hydroxychloroquine tablets. The company announced that it would supply hydroxychloroquine for clinical trials of preventive treatment of COVID-19. [11]

Generic APIs

Laurus Labs claims to be the "world's largest third party API supplier for anti-retrovirals" and has one of the largest [12] HiPotent API capacities in India [13] The company also makes Dolutegravir/lamivudine/tenofovir, a medication for HIV/AIDS, [14] [15] and hydroxychloroquine tablets, which are used to treat certain types of malaria. [16]

The company also manufactures oncology and cardiovascular APIs. [17] Laurus Labs supplies (APIs) to nine of the 10 largest generic pharma companies in the world. [17]

CDMO-Synthesis

Laurus Synthesis is the company's CDMO subsidiary. [18] The US, European Union and Japan are the three most important markets for Laurus Synthesis. [19]

Laurus Bio

Laurus Bio is the company's biotechnology subsidiary. Laurus Labs entered the biotechnology sector in 2020, by acquiring the Indian biotech company, Richcore. [20] Post the acquisition, Richcore was renamed to Laurus Bio Pvt Ltd, and became a subsidiary of Laurus Labs. [20] As of 2022, Laurus Bio has put into operation a 180 kilolitre fermentation capacity in food proteins. [21] [22]

Related Research Articles

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Biocon</span> Indian multinational biopharmaceutical company

Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics as well as biosimilar insulins and antibodies, which are sold in India as branded formulations. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets.

<span class="mw-page-title-main">Eisai (company)</span> Japanese pharmaceutical company

Eisai Co., Ltd. is a Japanese pharmaceutical company headquartered in Tokyo, Japan. It has some 10,000 employees, among them about 1,500 in research. Eisai is listed on the Tokyo Stock Exchange and is a member of the Topix 100 and Nikkei 225 stock indices.

The pharmaceutical industry in India was valued at an estimated US$42 billion in 2021 and is estimated to reach $130 billion by 2030. India is the world's largest provider of generic medicines by volume, with a 20% share of total global pharmaceutical exports. It is also the largest vaccine supplier in the world by volume, accounting for more than 60% of all vaccines manufactured in the world. Indian pharmaceutical products are exported to various regulated markets including the US, UK, European Union and Canada.

<span class="mw-page-title-main">Hetero Drugs</span> An Indian pharmaceutical company

Hetero Drugs is an Indian pharmaceutical company and the world's largest producer of anti-retroviral drugs. Hetero's business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.

<span class="mw-page-title-main">Genome Valley</span> Life Sciences in Telangana, India

Genome Valley is an Indian high-technology business district spread across 2,000-acre (8.1 km2)/(3.1 sq mi) in Hyderabad, India. It is located across the suburbs, Turakapally, Shamirpet, Medchal, Uppal, Patancheru, Jeedimetla, Gachibowli and Keesara. The Genome Valley has developed as a cluster for Biomedical research, training and manufacturing. Genome Valley is now into its Phase III, which is about 11 km from the Phase I and II with the total area approximately 2,000-acre (8.1 km2).

Torrent Pharmaceuticals Ltd is an Indian multinational pharmaceutical company, part of the Torrent Group and headquartered in Ahmedabad. It was promoted by U. N. Mehta, initially as Trinity Laboratories Ltd, and was later renamed Torrent Pharmaceuticals Ltd.

<span class="mw-page-title-main">Cambrex Corporation</span> American pharmaceutical company

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs). With over 2,200 employees in 7 countries across 13 locations, Cambrex operates in branded and generic markets for API and dosage form development and manufacturing.

<span class="mw-page-title-main">Patheon</span>

Patheon is a service brand within Thermo Fisher Scientific’s brand portfolio. Contract development and manufacturing organization (CDMO) services offered under the Patheon brand include small molecule API, biologics, viral vectors, cGMP plasmids, formulation, clinical trials solutions, logistics and commercial manufacturing and packaging. In 2017, Patheon was acquired by Thermo Fisher Scientific to form its Pharma Services business.

<span class="mw-page-title-main">Sun Pharma</span> Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries across the globe. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynecology, respiratory, oncology, dental and nutritionals. 

Hovione is a Contract Development and Manufacturing Organization (CDMO) with services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the United States, Portugal, Ireland and China development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione is also present in the inhalation area, and provides a complete range of services, from active pharmaceutical ingredients (APIs), formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corporation (certification), is a member of Rx-360 and EFCG.

<span class="mw-page-title-main">Vivimed Labs</span>

Vivimed Labs Limited is an India-based global supplier of specialty chemicals and pharmaceuticals. Headquartered in Hyderabad, India. Vivimed is a manufacturer of active pharmaceutical ingredients, active ingredients for home and personal care, hair dyes, imaging chemicals and photochromics.

<span class="mw-page-title-main">Lupin Limited</span> Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Unichem Laboratories is an Indian pharmaceutical company, headquartered in Mumbai. It manufactures and markets pharmaceutical formulations across the globe, including the regulated markets of the USA and Europe.

Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune. Emcure's product portfolio includes tablets, capsules and injectables. The company is a major producer of HIV antivirals, as well as gynaecology and blood therapeutic drugs.

<span class="mw-page-title-main">Aurobindo Pharma</span> Indian multinational pharmaceutical company

Aurobindo Pharma Limited is an Indian multinational pharmaceutical manufacturing company headquartered in HITEC City, Hyderabad, India. The company manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company’s area of activity includes six major therapeutic and product areas: antibiotics, anti-retrovirals, cardiovascular products, central nervous system products, gastroenterologicals, and anti-allergics. The company markets these products in over 125 countries. Its marketing partners include AstraZeneca and Pfizer.

Biotechnology in India is a sunrise sector within the Indian economy. Agencies of the Government of India concerned with the biotechnology industry include the Department of Biotechnology and the proposed Biotechnology Regulatory Authority of India. As of 2022, the sector is valued at $80 billion. Biotechnology in India is in a growth phase and the sector is expected to be valued at $150 billion by 2025 and surpass $300 billion in value by 2030.

Alembic Pharmaceuticals Ltd. is an Indian multinational pharmaceutical company headquartered in Vadodara. It is involved in the manufacture of pharmaceutical products, pharmaceutical substances and intermediates. It is also termed to be a market leader in macrolides segment of anti-infective drugs in India.

<span class="mw-page-title-main">Natco Pharma</span> Indian pharmaceutical company

Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and crop health science products, and also provides contract manufacturing services. It is a major producer of branded oncology medicines and hepatitis C drugs. The company specialises in producing complex medicines at affordable prices. In 2019, Natco launched its crop health sciences division.

<span class="mw-page-title-main">Divi's Laboratories</span> Indian pharmaceutical company

Divi's Laboratories Limited is an Indian multinational pharmaceutical company and producer of active pharmaceutical ingredients (APIs) and intermediates, headquartered in Hyderabad. The company manufactures and custom synthesizes generic APIs, intermediates. The company also manufactures and supplies nutraceutical ingredients through its subsidiary, Divi's Nutraceuticals. Divi's Laboratories is India's fourth largest publicly listed pharmaceutical company by market capitalization.

References

  1. ↑ "Laurus Labs Ltd". Bloomberg. Retrieved 17 April 2020.
  2. ↑ "Hyderabad-based Laurus Labs receives licence to manufacture 2DG". Telangana Today. 2 July 2021. Retrieved 27 January 2023.
  3. ↑ "Laurus Labs banking on vertical integration to crack anti-HIV tenders and US formulations mkts". Moneycontrol. Retrieved 17 April 2020.
  4. ↑ "Laurus Labs: A hot startup in the pharma sector". Forbes India. Retrieved 17 April 2020.
  5. 1 2 "Laurus Labs Q4 net slumps". The Hindu. 27 April 2023. Retrieved 27 June 2023.
  6. ↑ "India's Laurus Labs says four employees died in fire incident". Reuters. 27 December 2022. Retrieved 27 January 2023.
  7. ↑ "Laurus Labs Share Price: Company forays into Lucrative Biotech Space". Zee Business. 27 November 2020. Retrieved 27 November 2020.
  8. ↑ Sharma, Neetu Chandra (15 March 2022). "How Satyanarayana Chava Grew Laurus Labs". Business Today. Retrieved 29 March 2022.
  9. ↑ Trivedi, Isha. "Laurus Labs strikes gold by moving up the value chain. But there's a steeper climb ahead". The Economic Times. Retrieved 19 October 2020.
  10. ↑ "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 3. Retrieved 16 June 2022.
  11. ↑ "Coronavirus: Laurus Labs to supply Hydroxychloroquine for clinical trials in the US". Moneycontrol. Retrieved 17 April 2020.
  12. ↑ Laurus Labs. "Investor Presentation" (PDF).
  13. ↑ "Laurus Labs eyes bigger play in generic formulations segment". Times of India. Retrieved 17 April 2020.
  14. ↑ "Laurus Labs gets USFDA nod for HIV drug". Economic Times Health. Retrieved 17 April 2020.
  15. ↑ "Laurus Labs is ready to flood the US with cheap HIV drugs". Livemint. Retrieved 17 April 2020.
  16. ↑ "Laurus Labs gets USFDA nod for malaria tablets". The Hindu Business Line. Retrieved 17 April 2020.
  17. 1 2 ET Bureau (29 March 2022). "ET Emerging Company of the Year 2021: Laurus Labs-A pharma company beats the virus trap to make it big". The Economic Times. Retrieved 24 July 2022.
  18. ↑ Capital Market (12 January 2021). "Laurus Labs arm incorporates wholly-owned unit". Business Standard India. Retrieved 24 July 2022.
  19. ↑ "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 6. Retrieved 17 July 2022.
  20. 1 2 Ramarathinam, Ashwin (25 November 2020). "Laurus Labs buys 73% stake in Biotech firm Richcore Lifesciences for Rs247 crore". mint. Retrieved 29 March 2022.
  21. ↑ "Investors Presentation of the company" (PDF). www.nseindia.com/. NSE Website - Investors Presentation of the company. Quotes.
  22. ↑ "Laurus Labs Limited: Annual Report 2021-22" (PDF). Laurus Labs. 2022. p. 7. Retrieved 13 July 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.